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Objective: We previously identiﬁed an association between bone sialoprotein (BSP) and osteoarthritic
(OA) chondrocyte hypertrophy but the precise role of BSP in ostearthritis (OA) has not been extensively
studied. This study aimed to conﬁrm the association between BSP and OA chondrocyte hypertrophy, to
deﬁne its effect on molecules produced by chondrocytes and to analyse its association with cartilage
degradation and vascular density at the osteochondral junction.
Method: Human OA chondrocytes were cultivated in order to increase hypertrophic differentiation. The
effect of parathyroid hormone-related peptide (PTHrP), interleukin (IL)-1b or tumour necrosis factor
(TNF)-a on BSP was analysed by real-time reverse transcription polymerase chain reaction (RT-PCR) and
western blot. The effects of BSP on OA chondrocytes production of inﬂammatory response mediators (IL-
6, nitric oxide), major matrix molecule (aggrecan), matrix metalloprotease-3 and angiogenic factors
(vascular endothelial growth factor, basic ﬁbroblast growth factor, IL-8, and thrombospondin-1) were
investigated. BSP was detected by immunohistochemistry and was associated with cartilage lesions
severity and vascular density.
Results: PTHrP signiﬁcantly decreased BSP, conﬁrming its association with chondrocyte hypertrophy. In
presence of IL-1b, BSP stimulated IL-8 synthesis, a pro-angiogenic cytokine but decreased the production
of TSP-1, an angiogenesis inhibitor. The presence of BSP-immunoreactive chondrocytes in cartilage was
associated with the severity of histological cartilage lesions and with vascular density at the osteo-
chondral junction.
Conclusion: This study supports the implication of BSP in the pathology of OA and suggests that it could
be a key mediator of the hypertrophic chondrocytes-induced angiogenesis. To control chondrocyte hy-
pertrophic differentiation is promising in the treatment of OA.
 2014 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Osteoarthritis (OA) is a pathology affecting every joint tissue,
especially the cartilage that undergoes many structural and
biochemical modiﬁcations leading to its ﬁnal destruction. Manyto: Y. Henrotin, Institute of
ium. Tel: 32-4-3662516;
, christelle.sanchez@ulg.ac.be
Walsh), jean.pierre.delcour@
om (C. Baudouin), pmsika@
Henrotin).
ternational. Published by Elsevier Lpathways are implicated in damages of cartilage, including the
hypertrophic differentiation of chondrocytes. Indeed, in early and
late stage OA, some differentiated chondrocytes in permanent
articular cartilage are activated and acquire hypertrophy-like
changes1. This phenotypic changes are associated with the calciﬁ-
cation and neovascularisation of the extracellular matrix leading to
an increase of cartilage stiffness (for review, see2). Consequently,
chondrocyte hypertrophic differentiation has been hypothesized to
be a key event in OA progression (for review, see3).
Pathological chondrocyte hypertrophy is considered as a reit-
eration of the endochondral ossiﬁcation process normally absent in
normal adult cartilage4. Hypertrophic differentiation of chon-
drocytes participates to cartilage degradation in OA becausetd. All rights reserved.
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alloproteases (MMP) responsible for cartilage degradation in OA5.
As observed in the growth plate of growing individuals, the change
in cell phenotype is accompanied by invasion of articular cartilage
by blood vessels coming from the subchondral bone. Previous
studies have shown that in OA, channels containing vascular
structures may break the tidemark and invade the articular carti-
lage6e8. Vascular structures are usually accompanied by neural
invasion9. Moreover, vascular invasion, a process also called
angiogenesis, is associated with calciﬁcation of the extracellular
matrix.
The hypertrophic phenotype is characterized by a high
expression of speciﬁc markers such as type X collagen10e12, runt-
related factor 2 (runx2)13,14 or MMP-1315e17. A network of posi-
tive and negative regulatory factors controls chondrocyte hy-
pertrophy, this includes transcription factors, growth factors,
hormones, extracellular matrix molecules and proteases (for re-
view, see18).
We previously showed that bone sialoprotein (BSP) was
highly expressed by hypertrophic chondrocytes in comparison
with non-hypertrophic chondrocytes and was correlated to
speciﬁc markers of chondrocyte hypertrophy19. BSP is a major
non-collagenous extracellular matrix protein that belongs to the
small integrin-binding ligand N-linked glycoproteins (SIBLING)
gene family20. In physiological conditions, BSP is expressed by
mature osteoblasts, osteoclasts and hypertrophic chondrocytes of
the growth plate21e23. In these tissues, BSP is involved in
mineralization since its interaction with collagen promotes hy-
droxyapatite nucleation24,25. As a result, BSP is ﬁrstly known as a
marker of bone formation and has been considered as a marker
for subchondral bone for a long time26. In addition to its impli-
cation in tissue mineralization, BSP also promotes cell attach-
ment and signalling through its Arg-Gly-Asp (RGD) sequence and
alternate attachment mechanisms27,28 and has been further
described as an angiogenesis enhancer. Indeed, Bellahcène et al.
showed that BSP mediates human endothelial cell attachment
and migration through the interaction of its RGD domain with
endothelial cell avb3 integrin receptors29.
Hence, BSP constitutes a multifunctional protein with a large
clinical interest. We previously identiﬁed a preliminary association
between BSP and OA chondrocyte hypertrophy19 but the precise
role and regulation of BSP in OA remained to be extensively studied.
Herein, we investigated the effects of parathyroid hormone-related
peptide (PTHrP), interleukin (IL)-1b and tumour necrosis factor
(TNF)-a on BSP production by OA hypertrophic chondrocytes.
Further, we have investigated the effect of increased dose of BSP on
OA chondrocytes production of inﬂammatory response mediators
[IL-6, nitric oxide (NO)], a major matrix molecule [aggrecan (AGG)],
MMP-3 and angiogenic factors [vascular endothelial growth factor
(VEGF), basic ﬁbroblast growth factor (bFGF), IL-8, thrombospondin
(TSP)-1]. Finally, an immunohistological study performed on a set
of non-OA and OA cartilage sections demonstrated the association
between BSP localization, cartilage lesions severity and
vascularisation.
Material and methods
Chondrocytes culture in alginate beads
Culture settings
Human chondrocytes were isolated from cartilage of OA pa-
tients undergoing total knee replacement (TKR) surgery with the
approval of the Ethic Committee of Medicine department of the
University of Liege (number B70720108313, reference 2010/43).
Alginate beads were prepared as previously described30 and OAchondrocytes were embedded at a density of 4.2  106 cells
per millilitre alginate solution. OA chondrocytes in alginate
beads were cultivated for 3, 4, 8, 12, 21 or 28 days in
Dulbecco’s modiﬁed Eagle’s medium (DMEM) (Lonza, Verviers,
Belgium) either supplemented with 10 mM 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 20 mg/ml
proline (SigmaeAldrich, Bornem, Belgium), 50 mg/ml ascorbic acid
(SigmaeAldrich, Bornem, Belgium), 2 nM glutamine (Lonza,
Verviers, Belgium) and 10% (v/v) foetal bovine serum (FBS) (Lonza,
Verviers, Belgium) in order to induce hypertrophic differentiation
of OA chondrocyte, as previously validated19 or with 1% of a
preparation of insulin, transferrin, selenous acid, bovine serum
albumin (BSA), and linoleic acid (ITSþ) (ICN Biomedicals, Asse-
Relegem, Belgium) in order to test the effect of recombinant BSP
on OA chondrocyte. Media were changed twice a week. Some
chondrocytes in alginate beads were cultivated with either 20 nM
PTHrP, an inhibitor of hypertrophic differentiation (Abcam, Cam-
bridge, United Kingdom) or 170 pg/ml IL-1b (1011 M) or 25 ng/ml
TNFa (Roche Diagnostic, Vilvoorde, Belgium), two key cytokines
activating catabolic pathways of chondrocyte metabolism. These
concentrations correspond to the maximal IL-1b concentration
found in the synovial ﬂuid of patients31,32. These compounds were
added during the complete culture period of 28 days or only for
the last 7 days of the culture (þ7D), when OA chondrocytes
expressed a highly hypertrophic phenotype.
To investigate the effects of BSP on chondrocytes metabolism
and on the production of angiogenic factors, chondrocytes in algi-
nate beads were cultivated 12 days in medium supplemented with
1% ITSþ and increased concentrations of recombinant BSP (R&D
Systems, Abingdon, United Kingdom) that is 25, 100 and 400 ng/ml.
Each chondrocyte culture was realized from a pool of three to six
different OA patients that displayed a grade III or IV based on the
classiﬁcation tree for Collins grading of OA changes at the articular
surface33. Each culture condition was done in triplicate. Cultures
were repeated three times with different pools of chondrocytes
coming from different donors.
Gene expression and assays
Real-time reverse transcription polymerase chain reaction (RT-PCR)
of collagen type X and BSP
RNA from approximately 2  106 cells was isolated using the
RNeasy minikit (Qiagen, Hilden, Germany), and PCR was performed
using the LightCycler SYBR Premix Ex Taq system (Takara, Brussels,
Belgium) as previously described30. The PCR template source was
either 3 ng ﬁrst-strand complementary DNA (cDNA) or puriﬁed
DNA standard for calibration curve. The house-keeping gene hy-
poxanthine phosphoribosyltransferase (HPRT) was ampliﬁed and
used as an internal control to standardize messenger RNA levels.
Forward and reverse primer sequences used to amplify the desired
cDNA are respectively the following: HPRT: TGTAATGACCAGTCAA-
CAGGG and TGCCTGACCAAGGAAAGC; collagen type X (col10a1):
GGGAGTGCCATCATCG and AGGGTGGGGTAGAGTT; BSP:
GTGTCACTGGAGCCAA and ACCATCATAGCCATCGT.
Western blot analysis of BSP
Protein expression of BSP by chondrocytes was analysed by
western blotting with a mouse monoclonal anti-BSP antibody
(1:300) (LFMb-24, sc-73634; Santa Cruz Biotechnology Inc., Ger-
many). Protein concentrations were measured using the Micro BCA
Protein assay Kit (Thermo Scientiﬁc, Rockford, USA) according to
the manufacturer’s instructions. Equal amounts of protein were
separated in a 7.5% sodium dodecyl sulfate (SDS)-polyacrylamide
gel and were electrically transferred to polyvinylidene ﬂuoride
(PVDF) membrane. After incubation with goat anti-mouse
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Heverlee, Belgium), proteins were detected using enhanced che-
moluminescence reagent (ECLþ) (GE Healthcare, Diegem,
Belgium). Results were normalized compared to tubulin-a expres-
sion detected with mouse monoclonal antibody (1:1000) (sc-8035;
Santa Cruz Biotechnology Inc., Germany). Control condition was
constituted of human osteosarcoma Saos-2, known to produce
BSP34. These cell extracts were provided by theMetastasis Research
Laboratory, GIGA-Cancer at the University of Liege.
Immunoassays for TSP-1 and IL-8
TSP-1 (Duoset, R&D Systems, Abingdon, United Kingdom) and
IL-8 (EASIA, Biosource Europe, Fleurus, Belgium) were measured by
speciﬁc enzyme ampliﬁed sensitivity immunoassay directly in
chondrocytes conditioned culture media according to the manu-
facturer’s protocol.
Histology and immunohistochemistry study
Samples collection and processing
Cartilage biopsies were obtained from 24 patients undergoing
TKR for OA aged 68.96  9.388 (mean  SD, n ¼ 24) and from nine
non-arthritic controls collected post-mortem aged 50.67  18.81
(mean  SD, n ¼ 9). Cartilage degradation severity was evaluated
macroscopically according to the photographic chondropathy score
(PCS) described by Walsh et al35. Cartilage samples were ﬁxed in
neutral-buffered formalin and then wax embedded. Midcoronal
sections of medial tibial plateaux were decalciﬁed in 10% ethyl-
enediaminetetraacetic acid (EDTA) and 10 mM Tris buffer (pH 6.95)
at room temperature (RT) prior towax embedding. Fivemicrometre
thick tissue sections were cut with a microtome. All histological
scoring was undertaken by two different investigators, blinded to
patient group, using a Zeiss Axioscop-50 microscope.
Histology and grading of chondropathy
Tissue sections were stained with safranin-O to assess the
severity of microscopic OA changes in articular cartilage. After
nuclear staining withWeigert’s haematoxylin and dedifferentiation
in acid alcohol, sections were immersed in 0.02% fast green, then
0.1% safranin-O, and mounted. Microscopic histological evaluation
of OA severity in articular cartilage was evaluated using the
modiﬁed Mankin’s score36. Grades for the severity of OA were the
sum of four components: cartilage surface integrity [grade
0 (normal), grade 1 (surface irregularities), grade 2 (pannus and
surface irregularities), grade 3 (2 clefts to transitional zone), grade
4 (2 clefts to radial zone), grade 5 (2 clefts to calciﬁed zone),
grade 6 (complete disorganisation)], chondrocyte appearance
[grade 0 (normal), grade 1 (diffuse hypercellularity), grade 2
(cloning: a single chondron 5 nuclei), grade 3 (hypocellularity)],
proteoglycan loss [grade 0 (no loss of safranin-O stain), grade 1
(slight reduction), grade 2 (moderate reduction), grade 3 (severe
reduction), grade 4 (absence of staining)] and tidemark integrity [0
(intact) or 1 (crossed by vascular channels)]. Severity scores thus
can range between 0 (no observed changes) and 14 (most severe
changes).
Vascular structures immunostaining and counting
Blood vessels at the osteochondral junction were visualised
using a mouse monoclonal anti-CD34 antibody (clone QBEnd 10,
Dako, Cambridge, United Kingdom) directed against vascular
endothelium. Sections were deparafﬁnized in xylene and rehy-
drated in distilled water. The nonspeciﬁc binding sites were
blocked with horse serum (1:30) supplemented with 0.05%
BSA and sections were incubated with anti-CD34 antibody (1:40)
1 h at RT. A horse anti-mouse biotinylated secondary antibody(1:100) was used prior to reaction with alkaline phosphatase-
labelled ABC (both in vectastain ABC-PA kit, Vector Laboratories,
Peterborough, United Kingdom). Sections were mounted with
glycerol (1:10) and stored at 4C until examination. CD34 immu-
noreactive structures were visualised using FastRed (Sigmae
Aldrich, Dorset, United Kingdom). FastRed reaction product was
detected by transmitted light microscopy and also using its ﬂuo-
rescent properties under UV illumination (615 nm). Osteochondral
junction, calciﬁed and non-calciﬁed cartilage were discriminated
by autoﬂuorescence. The length of the tidemark was measured
using digital electronic callipers (Mitutoyo, Kawasaki, Japan).
Osteochondral vascular density was determined as the ratio be-
tween the number of vascular channels terminating in non-
calciﬁed articular cartilage and the length of the tidemark and
was expressed as number of vascular structure per millimetre of
tidemark.
BSP detection in cartilage
BSP was immunolocalized in cartilage using mouse monoclonal
antibody (LFMb-25, sc-73630; Santa Cruz Biotechnology Inc., Ger-
many). Brieﬂy, cartilage sections were deparafﬁnized in xylene and
rehydrated in distilled water. The blocking of endogenous peroxi-
dase was performed with 0.3% H2O2 in methanol and the nonspe-
ciﬁc binding sites were blocked with normal goat serum (1:30)
supplemented with 0.05% BSA. Anti-BSP antibody at dilution 1:100
was applied and incubated overnight at þ4C. A negative control
with a mouse IgG1 non-immune serum (Santa Cruz Biotechnology
Inc., Germany) at dilution 1:100 was included in the experiment.
The tissue sections were then incubated with biotinylated horse
anti-mouse antibody (1:100) (BA2001, Vector Laboratories, Peter-
borough, United Kingdom), followed by exposure to preformed
streptavidin-biotinylated HRP complex (ABC Elite, PK6100, Vector
Laboratories, Peterborough, United Kingdom). Peroxidase was
revealed by the 3,30-diaminobenzidine tetrahydrochloride reaction.
Sections were ﬁnally counterstained with haematoxylin, dehy-
drated and mounted.
Statistical analysis
Unless otherwise speciﬁed, data were analysed by one-way
analysis of variance (ANOVA) and if signiﬁcant, followed by
Tukey’s post-test and multiple comparisons test to obtain
adjusted P-values. The assumptions underlying the ANOVA were
assessed. Data were made of independent observations and the
homogeneity of variance between groups was analysed with the
Bartlett’s test but the number of sample in each group was too
small to test the normality. However, the ANOVA was used
because this statistical test is robust against violation of
normality. Multiplicity adjusted P-values account for the number
of comparisons between data groups for each experiment. The
multiple comparison tests report 95% conﬁdence interval for the
difference between means of each data group. The statistical
signiﬁcance threshold was set to 5%, this value applies to the
entire family of comparisons (experiment-wise error-rate).
Tukey’s test is a single-step multiple issue procedure that iden-
tiﬁes any difference between two means that is greater than the
expected standard error (SE) and corrects for experiment-wise
error-rate. The same uncertainty and limitations addressed to
the comparison between two groups, analysed with a Student’s t
test. Gaussian distribution of data was assessed with the D’Ag-
ostino and Pearson normality test. All data were analysed using
GraphPad Prism software, version 6. Production values were re-
ported to DNA content of the cells. The DNA content of the cul-
tures was measured according to the ﬂuorimetric method of
Labarca and Paigen38.
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In vitro investigation of BSP
The ﬁrst part of this study aimed to observe BSP gene expression
and protein production by OA chondrocytes incubated with or
without PTHrP, a speciﬁc inhibitor of chondrocyte hypertrophy or
IL-1b and TNFa, two major inﬂammatory cytokines. The effect of
recombinant BSP on the production of IL-6, NO, AGG, MMP-3, VEGF,
bFGF, IL-8 and TSP-1 by OA chondrocyte was also investigated in
this part of the study.Effect of PTHrP
Col10a1 gene expression was signiﬁcantly inhibited when
chondrocytes were continuously incubated with PTHrP (20 nM) for
21 days (P ¼ 0.0003; 91.53), or 28 days (P ¼ 0.0016; 94.38%) and
when PTHrP was added in the culture medium during the last 7
days of culture (between days 21 and 28) (P ¼ 0.0013; 97.12%)
[Fig. 1(A)]. These results indicated that PTHrP inhibited the
expression of a speciﬁc marker of chondrocyte hypertrophy. BSPFig. 1. Effect of PTHrP (20 nM), an inhibitor of chondrocyte hypertrophy, on collagen
type 10 expression (col10a1) and BSP expression and production by OA non-hyper-
trophic (day 3) and hypertrophic (days 21 and 28) chondrocytes. (A) Col10a1 was not
expressed by non-hypertrophic chondrocytes but well by hypertrophic chondrocytes.
Col10a1 expression was repressed when chondrocytes were cultivated with PTHrP
after 21 days (P ¼ 0.0003) and 28 days (P ¼ 0.0016) of culture and when PTHrP was
added for the last 7 days of culture (P ¼ 0.0013) (ANOVA: P < 0.0001). (B) BSP was not
expressed or produced by non-hypertrophic chondrocytes but its expression by hy-
pertrophic chondrocytes was repressed by PTHrP at day 21 (P ¼ 0.0009) and day 28
(P ¼ 0.0254) and when PTHrP was added for the last 7 days of culture (P ¼ 0.0243)
(ANOVA: P < 0.0001). Gene expression was analysed by RT-PCR and normalized by the
house-keeping gene HPRT. BSP production (65 kDa) by hypertrophic chondrocytes,
evaluated by western blot and normalized to tubulin-a (55 kDa), was clearly decreased
by PTHrP after 21 and 28 days of culture and slightly decreased when PTHrP was added
between days 21 and 28. Control (CTL) condition is constituted of Saos-2 cell extracts.
Independent observations were analysed by a single-step multiple comparison pro-
cedure (Tukey’s test) after one-way ANOVA and are presented in percentage of control
with the mean  95% conﬁdence interval. þ7D corresponds to the addition of PTHrP
for the last 7 days of culture only. Each data point is the mean of two measures per-
formed on three different chondrocytes cultures, each made from a different pool of
primary human chondrocytes coming from several different donors.genewas not expressed or produced during the first 3 days but well
after 21 and 28 days of culture when chondrocytes expressed a
hypertrophic phenotype and was almost completely inhibited
when PTHrP was added in the culture medium. A signiﬁcant inhi-
bition of 93.92  1.19% was observed after 21 days (P¼ 0.0009) and
of 95.94  1.38% after 28 days of incubation with PTHrP
(P ¼ 0.0254). A decrease of 92.83  5.9% of BSP expression by
chondrocytes was also observed when PTHrP was added from day
21 to 28 (P ¼ 0.0243) [Fig. 1(B)]. The production of BSP by chon-
drocytes analysed by western blot was also reduced by PTHrP after
21 and 28 days but the decrease was very small when PTHrP was
added for the last 7 days of culture [Fig. 1(A)]. A lactate dehydro-
genase activity (LDH) assay was performed to ascertain that
chondrocytes were not ongoing apoptosis. Whatever the culture
time or condition, cell death ratio remained below 5% (data not
shown).Effects of IL-1b and TNFa
After 3 days of culture, chondrocytes failed to express BSP and
IL-1b or TNFa did not induce BSP gene expression or BSP protein
production. At day 21 and 28, BSP was synthesized by chon-
drocytes. Addition of IL-1b (170 pg/ml) in the culture medium fully
blocked the expression of BSP by hypertrophic chondrocytes when
added continuously to the culture medium during 28 days
(P ¼ 0.0115) or when added from day 21 to 28 (P ¼ 0.012). TNFa
(25 ng/ml) also completely repressed BSP expression after 28 days
(P¼ 0.0139) andwhen added for the last 7 days (P¼ 0.0114) (Fig. 2).
BSP production was completely blocked by both cytokines as
attested by the western blot analysis (Fig. 2). IL-1b and TNFa also
fully repressed col10a1 expression after 21 or 28 days (P ¼ 0.0476
and P ¼ 0.0375 respectively) and when added from day 21 to 28
(P ¼ 0.0494 and P ¼ 0.0445, respectively) (data not shown). TheFig. 2. Effect of IL-1b (170 pg/ml) or TNFa (25 ng/ml) on BSP expression and pro-
duction by OA non-hypertrophic (day 3) and hypertrophic (days 21 and 28) chon-
drocytes. BSP was not expressed or produced by non-hypertrophic chondrocytes but
its expression by hypertrophic chondrocytes was repressed by IL-1b after 28 days
(P ¼ 0.0115) and when IL-1b was added to the culture medium from day 21 to 28
(P ¼ 0.012). TNFa also completely repressed BSP expression after 28 days
(P ¼ 0.0139) and when added for the last 7 days of culture (P ¼ 0.0114) (ANOVA:
P ¼ 0.0023). Gene expression was analysed by RT-PCR and normalized by the house-
keeping gene HPRT. BSP production (65 kDa), evaluated by western blot and
normalized to tubulin-a (55 kDa), was completely repressed by IL-1b and TNFa after
21 and 28 days of culture and when the cytokines were added to the medium for the
last 7 days of culture. Control (CTL) condition is constituted of Saos-2 cell extracts.
Independent observations were analysed by a single-step multiple comparison
procedure (Tukey’s test) after one-way ANOVA and are presented in percentage of
control with the mean  95% conﬁdence interval. þ7D corresponds to the addition
of IL-1b or TNFa for the last 7 days of culture only. Each data point is the mean of
two measures performed on triplicate conditions in three different chondrocytes
cultures, each made from a different pool of primary human chondrocytes coming
from several different donors.
Fig. 3. Immunoassay analysis of the expression of (A and B) TSP-1 and (C and D) IL-8 by OA chondrocytes cultivated in 1% ITSþ supplemented medium (control) under the inﬂuence
of recombinant BSP at 25 ng/ml (BSP 25), 100 ng/ml (BSP 100) or 400 ng/ml (BSP400) in basal (A and C) or IL-1b-stimulated (B and D) condition. IL-1b signiﬁcantly stimulated TSP-1
production after 8 (P < 0.0001) and 12 (P < 0.0001) days of culture. IL-1b-stimulated TSP-1 production was signiﬁcantly decreased by BSP at 25 ng/ml after 8 (P ¼ 0.0116) and 12
(P ¼ 0.0242) days of culture. IL-1b-stimulated IL-8 production was stimulated after 12 days of culture with recombinant BSP at 25 ng/ml (P ¼ 0.006), 100 ng/ml (P ¼ 0.0004) and
400 ng/ml (P ¼ 0.001). Independent observations were analysed by a single-step multiple comparison procedure (Tukey’s test) after one-way ANOVA and were normalized to DNA
content and presented as mean  SE cumulated in time. Each data point is the mean of three measures performed on triplicate conditions from three different chondrocytes
cultures, each made from a different pool of primary human chondrocytes coming from several different donors.
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viability (data not shown).
Effect of BSP on TSP-1 and IL-8 production by human OA
chondrocytes
BSP did not signiﬁcantly modify the basal production of TSP-1
and IL-8 by human OA chondrocytes whatever the dose and the
period of incubation [Fig. 3(A and C)]. IL-1b signiﬁcantly stimulated
TSP-1 production after 8 (P < 0.0001) and 12 days of culture
(P < 0.0001) and BSP 25 ng/ml decreased IL-1b-stimulated TSP-1
production after 8 and 12 days (P ¼ 0.0116 and P ¼ 0.0242,
respectively) [Fig. 3(B)] but increased IL-1b-stimulated IL-8 pro-
duction after 12 days at the concentration of 25 ng/ml (P ¼ 0.006),
100 ng/ml (P ¼ 0.0004) and 400 ng/ml (P ¼ 0.001) compared to
control condition without BSP [Fig. 3(D)].
Ex vivo investigation of BSP
The second part of this study aimed to localize BSP by immu-
nohistochemistry in OA and non-OA human cartilage sections. Age,
gender and data for PCS, Mankin score, vascular density and BSP
detection of the population considered in the ex vivo part of the
study are presented in Table I.
Analyse of cartilage degradation
PCS and Mankin score were signiﬁcantly higher in OA than in
non-OA cartilage (P < 0.0001). PCSs for OA and non-OA knee joint
were 67.4  15.78 (n ¼ 24) and 17.83  16.78 (n ¼ 9) respectively
(mean  SD) and the modiﬁed Mankin scores were 6.88  1.77 for
OA (n ¼ 24) and 2.33  2.12 for non-OA samples (n ¼ 9)
(mean  SD) (data not shown).
Analyse of vascular density
A signiﬁcant increase in vascular density was observed in OA
compared to non-OA samples (P ¼ 0.0029) as previouslyidentiﬁed9. Vascular density at the osteochondral junction of OA
and non-OA cartilage samples was 0.31  0.2 (n ¼ 24) and
0.10  0.13 (n ¼ 9) respectively (mean  SD) (data not shown).
Detection of BSP in cartilage
BSP-positive chondrocytes and extracellular matrix were
detected in articular cartilage of the whole group of OA patients
(n ¼ 24) and in three samples from the non-OA group (n ¼ 9). The
staining was mostly localized in the superﬁcial layer of articular
cartilage and chondrocytes localized around damaged ﬁbrillated
cartilage, namely in clusters, showed a dark staining for BSP (Fig. 4).
Association of BSP with cartilage degradation and vascular density
The presence of BSP in the whole collection of OA and non-OA
patients was associated with the severity of macroscopic cartilage
lesions assessed with the PCS (P < 0.0001) [Fig. 5(A)] and with the
modiﬁed Mankin score (P < 0.0001) [Fig. 5(B)]. A signiﬁcant asso-
ciation was also found with the individual scoring criteria of
cartilage surface integrity (P ¼ 0.0002) [Fig. 6(A)], chondrocyte
appearance (P < 0.0001) [Fig. 6(B)], proteoglycan loss (P ¼ 0.0081)
[Fig. 6(C)] and tidemark integrity (P ¼ 0.0158) [Fig. 6(D)]. The
presence of BSP in cartilage was also positively associated with
vascular density in cartilage samples (P ¼ 0.0094) (Fig. 7).
Discussion
Hypertrophic chondrocytes may contribute to cartilage degra-
dation and may support extracellular matrix mineralization and
neovascularization of the articular cartilage in OA. The successive
modiﬁcations leading to vascularization and mineralization of the
articular cartilage through phenotypic change of chondrocyte into
hypertrophy are observable in physiological (growth plate) and
pathological (OA) conditions. Hence, some factors involved in the
induction and regulation of chondrocyte hypertrophy in the growth
plate may constitute interesting targets to inhibit OA progression.
Table I
Characteristics of the immunohistochemistry study population. The PCS was obtained based on the method described by Walsh et al35. The Mankin score was calculated as
described in the Material and methods section. The vascular density corresponds to the ratio between the number of vascular structures and length of the tidemark (in
millimetre). For BSP, “þ” stands for presence of BSP and “” stands for absence of BSP. Data are presented in percentage (gender and BSP) or as mean  SD. NS: not speciﬁed
Age Gender PCS Mankin score Vascular
density
BSP
Surface
integrity
Chondrocytes
appearance
Proteoglycan
loss
Tidemark
integrity
Non-OA samples 46 M 4.2 0 0 0 1 0.28 
41 F 9.8 1 0 2 0 0 
26 M 7 0 1 0 0 0 
69 F 17 0 0 0 0 0 
70 M NS 2 2 1 1 0.28 þ
36 F 17 0 0 0 0 0 þ
29 M 7 0 1 1 0 0 
71 M 24.9 0 1 1 1 0.10 
68 M 55.7 1 2 1 1 0.27 þ
Mean  SD 50.67  18.81 M/F (%): 66.7/33.3 17.83  5.93 2.33  2.12 0.10  0.13 þ/ (%): 33.3/66.7
0.44  0.73 0.78  0.83 0.67  0.71 0.44  0.53
OA samples 81 M 91.25 2 2 2 1 0.27 þ
52 F 38.05 2 2 1 1 0.3 þ
81 M 86 2 3 2 0 0 þ
74 M 39.7 3 2 2 1 0.55 þ
57 M 53.4 1 2 2 1 0.44 þ
64 F 58.8 1 2 0 1 0.42 þ
63 M 44.85 2 2 2 1 0.32 þ
70 F 64.85 4 2 2 0 0 þ
84 F 79 3 1 2 1 0.7 þ
65 M 69.7 2 2 2 1 0.37 þ
76 M 79 4 1 2 1 0.34 þ
63 F 58.8 2 1 1 1 0.46 þ
73 F 61.9 2 1 1 0 0 þ
64 M 72.8 2 2 3 1 0.43 þ
78 M 69.3 3 2 2 1 0.12 þ
62 M 77.25 2 2 1 1 0.13 þ
60 M 66 3 2 2 0 0 þ
61 F 89.5 3 2 2 1 0.27 þ
78 F 46.4 2 2 2 1 0.23 þ
75 F 52.6 2 2 1 1 0.59 þ
61 F 73.75 1 1 2 1 0.16 þ
79 NS 76.3 2 2 2 1 0.36 þ
55 F 89.5 6 3 3 1 0.49 þ
79 M 79 2 2 1 1 0.38 þ
Mean  SD 68.96  9.39 M/F (%): 50/45.8 67.4  3.22 6.88  1.77 0.31  0.2 þ/ (%): 100/0
2.42  1.1 1.88  0.54 1.75  0.68 0.83  0.38
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chondrocyte hypertrophy. In this model, chondrocytes were
cultured in alginate beads for 28 days in serum-supplemented
medium in order to induce chondrocyte hypertrophic differentia-
tion19. Using this model, we have investigated the expression of
angiogenic factors by hypertrophic or non-hypertrophic cells. By
this way, we have identiﬁed BSP as the most upregulated pro-
angiogenic factor by OA hypertrophic chondrocytes in culture.
BSP was well correlated with the most relevant hypertrophic
markers like type X collagen, runx2 or MMP-13 suggesting that BSP
could be a key mediator of the hypertrophic chondrocyte mediated
cartilage vascularization. The present study conﬁrms the previous
one and brings new information on the role played by BSP in
cartilage degradation.
PTHrP is described as an inhibitor of chondrocyte hypertro-
phy39e41. Our results showed that PTHrP inhibited BSP expression
and production by OA hypertrophic chondrocytes conﬁrming that
BSP was related to the hypertrophic status of chondrocytes. As a
control of the inhibitory effect of PTHrP on chondrocyte hypertro-
phic differentiation, type X collagen expression was analysed. Type
X collagen was chosen as representative of the hypertrophic
phenotype of chondrocytes because it is the most widely accepted
marker of chondrocyte hypertrophy10e12. In regard of the reviewwritten by R. Dreier (Germany) who stated in conclusion that the
number of signalling molecules involved in chondrocyte prolifer-
ation and differentiation during endochondral ossiﬁcation also
plays a regulative role in articular cartilage during OA18, our results
conﬁrm that PTHrP regulates OA chondrocytes hypertrophy.
More surprising were the effects of IL-1b and TNFa on BSP and
type X collagen gene expression and protein production by hy-
pertrophic chondrocytes. These results suggest that pro-
inﬂammatory cytokines may repress the hypertrophic differentia-
tion of chondrocytes, consistent with evidence that they may also
globally inhibit chondrogenesis42,43. However, these results are not
in accordance with the rest of the work and can’t be convincingly
explained. One explanation would be that OA is the result of a
combination of mechanical, inﬂammatory and ageing related fac-
tors that is not mimicked by adding one single cytokine in the
culture medium of in vitro experiments.
To study the effect of BSP on the production of matrixmolecules,
catabolic or inﬂammatory mediators or other angiogenic factors,
concentrations of recombinant BSP added in the culture medium
were chosen according to data found in the literature and corre-
sponded to pathologic condition44e46. Production of NO, AGG,
MMP-3, IL-6, VEGF and bFGF was not modulated by BSP (data not
shown). BSP decreased chondrocyte production of TSP-1, an anti-
Fig. 4. BSP is detected on sections of OA cartilage by immunohistochemistry with a
monoclonal antibody. Representative pictures of three different sections of OA carti-
lage. (A) BSP-positive chondrocytes and extracellular matrix are localized in the su-
perﬁcial damaged layer of OA cartilage. (B) BSP is detected in clones of chondrocytes
located around damaged and ﬁbrillated cartilage. (C) Greater magniﬁcation of BSP-
positive clones of chondrocytes. Dark arrows indicate the surface of cartilage. Clear
arrow indicates the tidemark (magniﬁcation 5, 10 and 20).
L. Pesesse et al. / Osteoarthritis and Cartilage 22 (2014) 547e556 553angiogenic factor47 while it increased the production of IL-8, a pro-
angiogenic factor48e50. This could create an imbalance between
pro- and anti-angiogenic factors favourable to angiogenesis of
cartilage. These data are in accordance with those of Bellahcène
et al. demonstrating that BSP promotes angiogenesis29. These re-
sults also suggest that IL-8 is a key mediator of the BSP-induced
angiogenesis. Indeed, BSP had no effect on VEGF and bFGF, two
other well-known pro-angiogenic factors. Taken together, these
data support the hypothesis that BSP could be a key mediator of
cartilage neovascularisation mediated by hypertrophic
chondrocytes.
The ex vivo part of this study was essential to place our ﬁndings
in the context of human OA articular cartilage. BSP-positive chon-
drocytes were detected in OA cartilage tissue biopsies. As expected,
BSP was also detected in subchondral bone. The extent of BSP-
positive structures in bone seemed to increase with the severity
of the disease (data not shown). This observation is in accordance
with the results obtained by de Bri et al. on the guinea-pig model of
OA which suggested that altered BSP abundance could be a po-
tential bone marker for late stage OA51. However, this issue was not
particularly dealt with in this article since it focuses on cartilage.
The presence of BSP in growing cartilage and OA boneecartilagejunction has been described for several years by D. Heingard et al.
(Sweden) in two different animal models51,52. In 1995, Shen et al.
published results of a study in which they detected BSP mRNA in
hypertrophic chondrocytes of the femoral heads of growing rats by
in situ hybridization52. Later, de Bri et al. investigated the distri-
bution of BSP at the osteocartilaginous interface in the guinea pig at
different stages of primary OA by ultrastructural immunolocaliza-
tion. Their results showed that BSP immunolabelling was concen-
trated at the boneecartilage interface of the medial condyle in all
age groups and that the presence of BSP was increased in the OA
medial condyle compared to non-OA lateral condyle and was
correlated to cartilage ﬁbrillation in advanced OA. Both studies on
animal models of differentiating articular cartilage and of OA
notably concluded on an implication of BSP in the process of
mineralization. Compared to these studies, the novelty of our work
is that we detected BSP in human OA cartilage samples in order to
associate its presence with cartilage degradation and vascular
density at the osteochondral junction. Data showed a highly sig-
niﬁcant correlation between the presence of BSP and cartilage
degradation of OA human samples based on both macroscopic and
microscopic observations. Indeed, in OA samples, the presence of
BSP was associated with high severity of cartilage degradation.
Moreover, in non-OA samples, BSP was most of time undetectable
or only a light staining of chondrocytes in the superﬁcial layer of
cartilage was detected. Detailed association between BSP and
components of Mankin score revealed that cartilage surface
integrity, proteoglycan loss, chondrocyte appearance and tidemark
integrity were individually associated with the presence of BSP-
immunoreactive chondrocytes. The vascular density at the osteo-
chondral junction was associated with the Mankin score (r ¼ 0.67;
P < 0.0001) and with the PCS (r ¼ 0.54; P ¼ 0.0015) (data not
shown) conﬁrming that vascular density is associated with carti-
lage degradation as previously described8. Our results demon-
strated an association between the presence of BSP and vascular
density. These ﬁndings suggest that, as previously described in
other diseases, BSP could in part constitute a pro-angiogenic factor
in OA. This hypothesis is supported by the initial basic description
of BSP, characterized by the presence of a cell attachment recog-
nition RGD tripeptide sequence associated with the integrin-like
cell-binding receptor53.
In conclusion, results from the in vitro study conﬁrmed the as-
sociation of BSP with hypertrophic differentiation of chondrocytes
and suggested that BSP could be a promoter of cartilage angio-
genesis. The ex vivo part of the study allowed to detect an associ-
ation between the presence of BSP in cartilage and the severity of
this tissue degradation. In a previous work recently published19, we
showed that BSP was highly expressed, produced and released in
the culture medium of hypertrophic OA chondrocytes and that its
expression was correlated with markers of chondrocyte hypertro-
phy. Moreover, we showed that conditioned media from hyper-
trophic OA chondrocytes stimulated migration, invasion and
adhesion of endothelial cells, three essential steps of the angiogenic
process. We also demonstrated that an RGD domain protein was
implicated in the adhesion of endothelial cells mediated by hy-
pertrophic OA chondrocyte conditioned media. Consequently, re-
sults from our previous and present studies attested the potential
role of BSP in OA physiopathology and particularly in cartilage
vascularization. Indeed, in addition to its well described role in
mineralization of bone, its upregulation in osteotropic cancers and
its pro-angiogenic effect on endothelial cells, BSP may now be
associated with cartilage degradation, chondrocyte hypertrophy
and neovascularization of the articular cartilage in the pathology of
OA. However, these conclusions should be tempered by the limi-
tations of this study: (1) we lack of information regarding the hy-
pertrophic differentiation and angiogenic activity of normal
Fig. 5. Comparison of cartilage degradation scores between samples in which BSP was absent and those in which BSP was present. Cartilage samples come from biopsies from OA
(n ¼ 24) and non-OA (n ¼ 9) patients. The photographic chondropathy score (PCS) was obtained based on the method described byWalsh et al35. The Mankin score was calculated as
described in the Material and methods section. (A) PCS and (B) the Mankin score were higher in cartilage in which BSP was present (P < 0.0001). Data were analysed by Student’s t
test and are presented as mean  95% conﬁdence interval.
L. Pesesse et al. / Osteoarthritis and Cartilage 22 (2014) 547e556554chondrocytes; (2) we don’t know the effect of BSP on healthy
chondrocytes; (3) we can’t convincingly explain why IL-1b and
TNFa decrease BSP and ﬁnally (4) we failed to present a direct
demonstration that BSP is the pro-angiogenic factor responsible for
the angiogenic effect of hypertrophic chondrocytes. Regarding this
last issue, one solution would be to block BSP activity by neutral-
izing antibodies in order to perform functional experiments.Authors contributions
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